Skip to main content
Equibles
DNLI logo

DNLI · Denali Therapeutics Inc.

Track DNLI — free

Use DNLI with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DNLI

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$24.92 -0.03 (-0.12%) At close · Aug 21
Market Cap
$3.98B
Shares
159.85M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$24.92 Open$25.25 Day$24.60–25.37 52W close$12.75–27.21 Avg vol 30d1.6M Short int17.4M · 10.9% float · 12.1d Short vol46% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Dec 23, 2026 Est · unconfirmed · in 17 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol High
Market backdrop VIX 15.1 · calm Equity put/call 0.51
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +22%
above
Price vs 50-day avg +2%
above
RSI (14) 54
neutral
MACD trend Positive
52-week position 84%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +8%
trailing
6-month return +19%
trailing
YTD return +51%
this year
Relative strength +7%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $24 › 200d $20 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +54 funds added
Insider flow Distributing
Net -$71.6K over 90 days · 100% sells
Short interest Rising
10.91% of float · ▲ +8.7% MoM · 12.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
293 holders — near 3-yr high, broad support
Squeeze score 69
elevated · 0–100
Fundamentals
Weak
EPS growth −16%
Y/Y
Free cash flow $-422.1M
Balance sheet $205.3M
net cash
Quant / Vol
risk profile
High
Volatility 57%
annualized · 1-yr
Max drawdown −20%
past year
ATR 3.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 6, 2026
AVLAYAH net product revenue · third quarter 2026 Initiated $10M – $12M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+22% Bullish
Price vs 50-day avg
+2% Bullish
RSI (14)
54 Neutral
MACD trend
Positive Bullish
52-week position
84% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $24 › 200d $20 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +54 funds added
Insider flow Distributing
Net -$71.6K over 90 days · 100% sells
Short interest Rising
10.91% of float · ▲ +8.7% MoM · 12.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
293 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13 Now $25 · 84% Range high $27
vs 200-day avg +22% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Enrollment in the study 40 Phase 1/2 study —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DNLI
Denali Therapeutics Inc.
this stock
$3.98B +50.9% — — 10.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.91B +20.9% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.66B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $57.97B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
293
% held
98.4%
Net QoQ
+9.0M sh
Top holder
T. Rowe Price Investment…
Held Float
View
Held by Funds
Fund positions
280
View
Short & Settlement
Short Interest Rising
Shares short
17.4M
Days to cover
12.1d
Change
+1.4M sh
View
Short Volume
Short vol %
46%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
40
Value
$921
As of
Jul 16, 2026
View
Off-Exchange
Off-exchange %
44.4%
Week of
Jul 13, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$71.6K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-512.5M
EPS diluted
$-2.97
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
17
View
Proposed Sales
Value
$801.4K
Shares
39.5K
Filed
Feb 5, 2026
View
Exempt Offerings
Offering
$499.7M
Filed
Mar 1, 2024
View
Earnings & Events
Earnings Calls
Last call
Aug 6, 2026
View
Investor Relations
Latest news
Denali Therapeutics Reports Secon…
Published
Aug 6, 2026
View

Performance

5D 20D 120D MTD YTD
DNLI +2.1% +7.8% +18.7% +8.3% +50.9%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +3.5% +4.2% +7.1% +5.8% +38.7%
Key facts CIK 1714899 CUSIP 24823R105 13F (30d) 268 filings 261 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)